Nemaline Myopathy 6 (NEM6) Cell Models for Research

Nemaline myopathy 6 (NEM6) is a rare congenital myopathy with an estimated prevalence of 1 in 50,000 live births (WHO, 2023). It is characterized by muscle weakness, hypotonia, and the presence of rod-like structures (nemaline bodies) in muscle fibers. The disease is progressive, with variable severity ranging from mild to severe. Respiratory complications are a major cause of morbidity and mortality, with a 5-year survival rate of approximately 70% in severe cases (NCI, 2022). There is no cure, and current management is supportive, making research into disease mechanisms and therapies critical.

NEM6 is an ideal model for studying muscle development, sarcomere assembly, and protein aggregation. The disease is caused by mutations in the KBTBD13 gene, which encodes a protein involved in ubiquitination and protein degradation. The availability of patient-derived cell lines and the relatively simple genetic basis (single gene) make it amenable to gene editing. Public datasets, such as those from the Muscular Dystrophy Association and the NIH, provide valuable resources for studying disease mechanisms. Open questions include the precise role of KBTBD13 in muscle function and the development of targeted therapies.

The pathogenesis of NEM6 involves several key pathways:

1. Ubiquitin-Proteasome System (UPS): KBTBD13 is a substrate adaptor for Cullin-RING E3 ligases, targeting proteins for degradation. Mutations impair this process, leading to accumulation of toxic proteins.

2. Sarcomere Assembly: Disrupted protein degradation affects sarcomere structure, leading to nemaline rod formation.

3. Autophagy: Impaired UPS may also affect autophagy, contributing to protein aggregation.

4. Calcium Signaling: Altered protein turnover may impact calcium handling in muscle cells, affecting contraction.

Data from TCGA and COSMIC (2023).

Key signaling networks deregulated in NEM6 include:

• • Ubiquitin-Proteasome Pathway: Key nodes: KBTBD13, Cullin-3, Rbx1.
• • Autophagy Pathway: Key nodes: LC3, p62, Beclin-1.
• • Calcium Signaling: Key nodes: RyR1, SERCA, calmodulin.
• • Muscle Differentiation: Key nodes: MyoD, Myogenin, MEF2.

Organoids derived from iPSCs can recapitulate muscle development and are useful for studying disease mechanisms and drug screening.

• • GEMM (Genetically Engineered Mouse Model): Kbtbd13 knockout mice show muscle weakness and nemaline rods.
• • Induced Models: CRISPR-induced mutations in zebrafish or mice.
• • PDX (Patient-Derived Xenograft): Not typically used for myopathies, but muscle organoid xenografts are emerging.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise mutations in KBTBD13. For example, a KBTBD13 knockout line can be generated in C2C12 cells to study loss-of-function effects, while a knock-in line with the common R225C mutation can model the dominant-negative effect. These sequence-verified models are commercially available from various suppliers and provide a reliable platform for drug screening and functional studies. They eliminate the variability of patient-derived cells and allow for high-throughput assays.

Knockout and knock-in lines are used to validate the role of KBTBD13 in muscle function. For example, CRISPR knockout of Kbtbd13 in C2C12 cells leads to impaired myotube formation and altered expression of muscle-specific genes. Knock-in of the R225C mutation recapitulates the protein aggregation phenotype, allowing mechanistic studies.

Isogenic pairs (wild-type vs. mutant) are ideal for high-throughput drug screening. Compounds that reduce nemaline rod formation or improve muscle function can be identified. Resistance to therapies can be modeled by exposing cells to increasing drug concentrations and selecting for resistant clones.

CRISPR-based synthetic lethality screens can identify genes that are essential only in the context of KBTBD13 mutations, revealing potential therapeutic targets. Additionally, secretome analysis of mutant cells can identify biomarkers for disease progression.